Condition

Pre-Exposure Prophylaxis of HIV Infection

ClinicalTrials.gov condition label

Clinical trials6

Recruiting0

Common interventions14

Lead sponsors shown2

Clinical trials

6 shown

Evaluating the Healthy Families PrEP Program for Women at Risk for HIVNCT06746675 · 2026-08-01

NOT_YET_RECRUITING

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312 · 2024-10-07

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · 2023-12-13

ACTIVE_NOT_RECRUITING

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · 2023-11-17

ACTIVE_NOT_RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionNCT04994509 · 2021-08-30

ACTIVE_NOT_RECRUITING

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionNCT04925752 · 2021-06-28

ACTIVE_NOT_RECRUITING

Common interventions

Emtricitabine/tenofovir disoproxil fumarate (F/TDF)DRUG3Lenacapavir InjectionDRUG3Lenacapavir TabletDRUG3F/TDFDRUG2Oral Lenacapavir (LEN)DRUG2Placebo SC LENDRUG2PTM F/TDFDRUG2PTM Oral LENDRUG2F/TAFDRUG1F/TAF (for US participants only)DRUG1Healthy Families PrEP Counselling InterventionDRUG1PTM F/TAFDRUG1Sub-cutaneous (SC) Lenacapavir (LEN)DRUG1Subcutaneous (SC) Lenacapavir (LEN)DRUG1

Leading sponsors

Gilead Sciences5Yale University1

Trial status mix

ACTIVE_NOT_RECRUITING5

NOT_YET_RECRUITING1

Phase mix

PHASE23

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.